Literature DB >> 19616901

A small tolerance for catheter displacement in high-dose rate prostate brachytherapy is necessary and feasible.

Albert Tiong1, Sean Bydder, Martin Ebert, Nikki Caswell, David Waterhouse, Nigel Spry, Peter Camille, David Joseph.   

Abstract

PURPOSE: We examined catheter displacement in patients treated with fractionated high-dose rate (HDR) brachytherapy boost for prostate cancer and the impact this had on tumor control probability (TCP). These data were used to make conclusions on an acceptable amount of displacement. METHODS AND MATERIALS: The last 20 patients treated with HDR brachytherapy boost for prostate cancer at our center in 2007 were replanned using simulated interstitial catheter displacements of 3, 6, 9, and 12 mm with originally planned dwell times. The computer-modeled dose-volume histograms for the clinical target volumes were exported and used to calculate the TCP of plans with displaced needles relative to the original plan. Actual catheter displacements were also measured before and after manual adjustment in all patients treated in 2007.
RESULTS: In the 20 patients who were replanned for caudal catheter displacements of 3, 6, 9, and 12 mm, the median relative TCP was 0.998, 0.964, 0.797, and 0.265, respectively (p < 0.01 when all medians were compared). All patients replanned with a 3-mm displacement, compared with only 75% with a 6-mm displacement, had a relative TCP greater than 0.950. In the 91 patients treated in 2007, before adjustment, 82.3% of fractions had a displacement greater than 3 mm compared with 12.2% of fractions after adjustment.
CONCLUSIONS: Catheter displacement in HDR brachytherapy significantly compromises the TCP. The tolerance for these movements should be small (< or =3 mm). Correcting these displacements to within acceptable limits is feasible. Crown Copyright 2010. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19616901     DOI: 10.1016/j.ijrobp.2009.03.052

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Improved electromagnetic tracking for catheter path reconstruction with application in high-dose-rate brachytherapy.

Authors:  Elodie Lugez; Hossein Sadjadi; Chandra P Joshi; Selim G Akl; Gabor Fichtinger
Journal:  Int J Comput Assist Radiol Surg       Date:  2017-02-18       Impact factor: 2.924

2.  Multi-needle Localization with Attention U-Net in US-guided HDR Prostate Brachytherapy.

Authors:  Yupei Zhang; Yang Lei; Richard L J Qiu; Tonghe Wang; Hesheng Wang; Ashesh B Jani; Walter J Curran; Pretesh Patel; Tian Liu; Xiaofeng Yang
Journal:  Med Phys       Date:  2020-04-03       Impact factor: 4.071

3.  Prostate external beam radiotherapy combined with high-dose-rate brachytherapy: dose-volume parameters from deformably-registered plans correlate with late gastrointestinal complications.

Authors:  Calyn R Moulton; Michael J House; Victoria Lye; Colin I Tang; Michele Krawiec; David J Joseph; James W Denham; Martin A Ebert
Journal:  Radiat Oncol       Date:  2016-10-31       Impact factor: 3.481

4.  HDR prostate brachytherapy plan robustness and its effect on in-vivo source tracking error thresholds: A multi-institutional study.

Authors:  Joel Poder; Dylan Koprivec; Yashiv Dookie; Andrew Howie; Dean Cutajar; Antonio L Damato; Nicolas Côté; Marco Petasecca; Joseph Bucci; Anatoly Rosenfeld
Journal:  Med Phys       Date:  2022-04-19       Impact factor: 4.506

5.  Catheter displacement prior to the delivery of high-dose-rate brachytherapy in the treatment of prostate cancer patients.

Authors:  Shogo Kawakami; Hiromichi Ishiyama; Tsuyoshi Terazaki; Itaru Soda; Takefumi Satoh; Masashi Kitano; Shinji Kurosaka; Akane Sekiguchi; Shouko Komori; Masatsugu Iwamura; Kazushige Hayakawa
Journal:  J Contemp Brachytherapy       Date:  2014-06-24

6.  Robustness of IPSA optimized high-dose-rate prostate brachytherapy treatment plans to catheter displacements.

Authors:  Joel Poder; May Whitaker
Journal:  J Contemp Brachytherapy       Date:  2016-06-13

7.  Dosimetric assessment of prostate cancer patients through principal component analysis (PCA).

Authors:  Aime M Gloi; Robert Buchanan
Journal:  J Appl Clin Med Phys       Date:  2013-01-07       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.